(+/-)-6-Methyl-N-(methylsulfonyl)-2-(3-((2-(trifluoromethyl)-phenoxy)methyl)pyrrolidin-1-yl)pyrimidine-4-carboxamide

ID: ALA4752884

Chembl Id: CHEMBL4752884

PubChem CID: 162652957

Max Phase: Preclinical

Molecular Formula: C19H21F3N4O4S

Molecular Weight: 458.46

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  Cc1cc(C(=O)NS(C)(=O)=O)nc(N2CCC(COc3ccccc3C(F)(F)F)C2)n1

Standard InChI:  InChI=1S/C19H21F3N4O4S/c1-12-9-15(17(27)25-31(2,28)29)24-18(23-12)26-8-7-13(10-26)11-30-16-6-4-3-5-14(16)19(20,21)22/h3-6,9,13H,7-8,10-11H2,1-2H3,(H,25,27)

Standard InChI Key:  DBIWVUQOUFOQDI-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4752884

    ---

Associated Targets(Human)

RBP4 Tchem Plasma retinol-binding protein (718 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TTR Tclin Transthyretin (2847 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 458.46Molecular Weight (Monoisotopic): 458.1236AlogP: 2.40#Rotatable Bonds: 6
Polar Surface Area: 101.49Molecular Species: ACIDHBA: 7HBD: 1
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski):
CX Acidic pKa: 3.76CX Basic pKa: 2.24CX LogP: 2.13CX LogD: 1.33
Aromatic Rings: 2Heavy Atoms: 31QED Weighted: 0.71Np Likeness Score: -1.57

References

1. Cioffi CL,Muthuraman P,Raja A,Varadi A,Racz B,Petrukhin K.  (2020)  Discovery of Bispecific Antagonists of Retinol Binding Protein 4 That Stabilize Transthyretin Tetramers: Scaffolding Hopping, Optimization, and Preclinical Pharmacological Evaluation as a Potential Therapy for Two Common Age-Related Comorbidities.,  63  (19): [PMID:32878437] [10.1021/acs.jmedchem.0c00996]

Source